tiprankstipranks
Trending News
More News >

Accelerate Diagnostics price target lowered to $1 from $2 at Craig-Hallum

Craig-Hallum lowered the firm’s price target on Accelerate Diagnostics to $1 from $2 and keeps a Hold rating on the shares. As outlined in the preliminary release, Q4 results continued to present challenges for Accelerate, the firm says. Specifically, Beckton Dickinson still has yet to gain momentum, few Pheno systems were placed, consumable sales declined quarter-over-quarter, and the capital position remains tight – even with a $15M equity raise in January. One bright spot in the quarter was the continued progress on Wave, says Craig-Hallum.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue